Reviews on remdesivir in Covid-19 treatment
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
A forum for researchers, students and applicants in the field of cyclodextrin technology
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19
Sedor Pharmaceuticals, LLC (Sedor) announced on November 9, 2020 that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT
Currently, remdesivir is only available as a lyophilized powder for reconstitution and intravenous53 infusion and concentrate solution for dilution and
A very few patent applications may trace back prior art disclosure to the Neolithic Age (from 10000 – 4500 BC)
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1)
Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is
Science News reported on October 5, 2020 the opinion of Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital